Introduction
Colorectal cancer is the third most commonly diagnosed cancer in males and the second in females, with an estimated 1.4 million new cases and 693,000 deaths in 2012. The highest incidence rates are found in Australia, New Zealand, Europe, and Northern America. 1 While incidence rates are rising, mortality rates in colorectal cancer are decreasing, most likely due to increased screening, reduced prevalence of risk factors, and improved treatments for early stage disease. 2, 3 In spite of these advancements, up to 80% of patients with colorectal liver metastases (CRLM) present with advanced stage disease at the time of diagnosis that is not amenable to surgery. [4] [5] [6] [7] In a setting of metastatic liver disease, minimally invasive therapies, such as irreversible electroporation (IRE), 8, 9 microwave ablation (MWA), radiofrequency ablation (RFA), or selective internal radiation therapy, are possible adjunct treatment options that can be performed after systemic or regional chemo-and immunotherapy. 4 For patients with inoperable CRLM not suitable for thermal ablation techniques, IRE is a novel local treatment option in addition to chemo-and immunotherapies. 10, 11 IRE is a nonthermal ablation procedure still under early clinical investigation. 12 In contrast to techniques using thermal ablation, the electrical field in
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schicho et al IRE initially causes apoptosis instead of necrosis. Ultra-short high-voltage currents cause lethal pores in the cell membrane of tumor tissue, resulting in breakdown of the transmembrane potential 13 via creation of nanopores in the cell membrane. With subsequent influx and efflux of ions through the lipid bilayer, apoptosis, rather than necrosis, is induced, at least initially.
14 This allows for ablation of metastases aligned with critical structures, such as vessels or adjacent organs. Data on patient survival after percutaneous IRE are scarce. 9 Herein, we report the results of long-term follow-up of 24 patients with inoperable CRLM who underwent IRE.
Materials and methods
Twenty-four sequential patients with inoperable liver metastases from colorectal cancer treated with IRE (NanoKnife ® , Latham, NY, USA) before July 2015 were included in this retrospective long-term follow-up study. Initially, all cases were individually discussed in the interdisciplinary tumor board, and all physicians involved agreed on IRE treatment. Inclusion criteria were as follows: CRLM, age >18 years, informed consent, and ineligibility for thermal ablation or surgery. Exclusion criteria covered any contraindication for general anesthesia, cardiac pacemakers or ICD, vascular infiltration, CRLM with extrahepatic spread, preexisting cardiac conditions such as arrhythmias or significant heart failure, and severe coagulopathies. The University of Regensburg Institutional Review Board waived approval for this study due to the retrospective and fully anonymized character. All patient data were kept strictly confidential, and all requirements of the Declaration of Helsinki were fulfilled. In accordance with international, national, and local requirements, all patients provided written consent prior to IRE treatment. 15, 16 All IRE procedures were performed under general anesthesia and as described previously. 17 Follow-up imaging (MRI of the liver using a liver-specific contrast agent [Gd-EOB-DTPA]) was acquired 6 weeks post-IRE, quarterly for 2 years, and semi-annually thereafter.
Kaplan-Meier survival curves were calculated and plotted using GraphPad Prism version 5.00a for Mac (GraphPad Software, San Diego, CA, USA). Log-rank statistics were calculated to identify factors of prognostic value for survival after either diagnosis or first IRE. Investigated variables included TNM tumor (T)/lymph node (N)/distant metastases (M) characteristics on diagnosis, gender, short axis diameter of IRE-treated lesions, and number of hepatic metastases. Age (young/old) and time of IRE (early/late) were grouped by the median cutoff. Survival was defined as either the time from diagnosis or the time from first IRE to death from any cause. Patients alive at the date last known were censored.
A value of P<0.05 for alpha was considered a statistically significant difference. For anonymized retrospective analyses, approval from the institutional ethics committee was waived.
Results
We included 24 patients with inoperable CRLM and IRE in our long-term follow-up study. Eighteen (75.0%) were male, and the median age was 57 years, with a range of 28-75 years. Table 1 contains additional baseline characteristics.
At the time of diagnosis, 70.8% (n=17) of patients had stage T3 or T4 tumors, 66.7% (n=16) had lymph node metastases (N1 or N2), and 87.5% (n=21) had metastatic disease. Further baseline characteristics of the tumors are shown in Table 2 Figure 1B) .
Overall survival was 26.5 months after IRE (range: 2.5-69.2 months) and 58.1 months after diagnosis (range: 14.8-180.1 months). One-, three-, and five-year survival rates after IRE were 79.1%, 25.0%, and 8.3%; the respective survival rates after initial diagnosis were 100.0%, 79.2%, and 41.2% (Table 3 ). 
Discussion
Percutaneous ablation techniques have become a treatment option with several indications, including inoperable liver malignancies. While thermal ablation techniques, such as RFA or MWA, are limited by the so-called heat sink effect, nonthermal ablation with IRE is advantageous in the treatment of liver lesions adjacent to great vessels. IRE does not cause damage to intact adjacent structures, such as bile ducts, 18 vessels, gall bladder, diaphragm, or heart, reducing the risk of complications. With advanced stage disease, patients in our cohort received IRE as a last treatment option. Since it is known that incomplete ablation of liver lesions causes decreased survival 19 due to local recurrence [20] [21] [22] and simultaneous tumor spread, 23 IRE is very valuable for inoperable CRLM. 24 In this palliative setting, our study was solely focused on survival, not covering local recurrence as primary or secondary end points. Ruers et al were the first to show that aggressive local treatment of CRLM, in addition to chemotherapy, prolongs overall survival. 25 For hepatic metastases, IRE is the very last nonsystemic treatment option. It can even be suitable for lesions not amenable to surgery or thermal ablation. For CRLM, we observed a median survival of 26.6 months after the first IRE, which is markedly longer than that for the usual systemic treatment approaches alone. After completion of chemotherapy with fluorouracil and oxaliplatin, a median survival of 19.5 months has been reported, 26 and for irinotecan, fluorouracil, and leucovorin, a median survival of 14.8 months was observed. 27 Following chemotherapy with irinotecan and fluoropyrimidine, additional treatment with bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin conveyed an additional median survival of 12.9 months. 28 From the time of diagnosis, our cohort reached a median survival of 58.1 months. Song et al compared MWA and resection of operable CRLM, not giving details on survival; however, an overall survival of little >60 months for MWA can be estimated. 29 In our cohort, all patients were pretreated, and IRE was an additional therapeutic modality implemented in case with no alternative. The cases included in this cohort were not only inoperable but were also not amenable to thermal ablation. Thus, comparable data concerning survival benefits are very limited. van Iersel et al report a median survival of 25.0 months for isolated hepatic perfusion and 21.7 months for capecitabine, irinotecan, and oxaliplatin in isolated nonresectable CRLM. 30 Solbiati et al report a 5-year survival of 47.8% for RFA added to systemic chemotherapy in patients not eligible for surgery or who refused surgery, compared to 41.2% in our cohort, 31 comprised of patients who underwent various other therapies before IRE. For RFA as salvage therapy after hepatectomy, a 3-year survival of 41% was reported, compared to 25.0% (after IRE) and 79.2% (after diagnosis) in our cohort. 32 Due to the small cohort and retrospective study design, it is difficult to draw broad conclusions concerning the value of IRE in the treatment of secondary, inoperable liver malignancies. With a median survival longer than standard chemotherapy regimens, IRE should be regarded as the option-of-choice for patients with inoperable liver metastases who are not suitable for thermal ablation procedures. Further prospective randomized studies with a larger number of patients are needed to evaluate the value of IRE in the setting of CRLM. Moreover, detailed analysis of additional biomarkers, such as KRAS, 33 as prognostic indicators is needed. 34, 35 In light of IRE being without an alternative in selected cases, 17,36-38 a median survival of 26.6 months after first IRE is a promising result. Thus, we conclude that IRE is a valuable therapy for patients with CRLM not amenable to surgery or thermal ablation.
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